Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics

Published:2021-01-20 Issue:3 Volume:39 Page:175-177
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Gyawali Bishal¹²³,West Howard (Jack)⁴

Affiliation:

1. Department of Oncology, Queen's University, Kingston, Canada

2. Department of Public Health Sciences, Queen's University, Kingston, Canada

3. Division of Cancer Care and Epidemiology, Queen's University, Kingston, Canada

4. Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.01762

Reference12 articles.

1. Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

2. Making adjuvant therapy decisions with uncertain data

3. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

4. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

5. Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non–Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

2. Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?;CLIN LUNG CANCER;2024

3. Patients' Preferences for Adjuvant Osimertinib in Non–Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?;Clinical Lung Cancer;2024-09

4. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward;eClinicalMedicine;2024-09

5. Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations;The Lancet Oncology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3